These are the core biochemical features in the study of GBA1 mutations in PD as expressed in PD brain (Gegg et al., 2012) and provide a model with which to test therapeutic interventions to manipulate the GCase-α-synuclein pathway. Here, GBA1 is linked to Parkinson disease.